Bojian capsule acquires TMS-007 for a new generation of thrombolytic therapy

On May 12, 2021, Biogen and TMS jointly announced that Biogen will exercise the option to acquire TMS-007, a drug under development for the treatment of acute ischemic stroke (AIS) from TMS.

Stroke is a debilitating and even fatal cerebrovascular event.

TMS-007 is a small molecule plasminogen activator, which has a potential new mechanism of action in breaking down blood clots, and can inhibit local inflammation caused by thrombosis and restore blood flow after acute stroke.

Bojian’s decision to acquire TMS-007 is based on positive data from a Phase 2a clinical trial.

The results of the trial showed that TMS-007 reached the primary end point of safety.

Bojian is currently evaluating the next steps in clinical development of TMS-007, including plans to conduct global clinical studies.

Reference materials:

[1] Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data.